Table 2.

Laboratory parameters, Imaging and clinical outcomes of four cases presenting with Covid-19 associated GBS.

Case	Chest X ray	NCS findings	CSF	MRI spine	Treatment	Outcome
1	Normal	Pure motor axonal polyneuropathy	Protein: 54 mg% Glucose:114 mg%	Mild degenerative changes.	IVIG: 2 g/kg over 5 days	Good improvement (Able to walk independently at discharge)
			Cells = 5 cells/cmm; all lymphocytes	No Cord changes
				No nerve root enhancement
2	Ill-defined inhomogeneous infiltrates involving predominantly the upper lobes	Severe demyelinating sensorimotor polyneuropathy affecting all 4 limbs with evidence of conduction block involving both ulnar nerves.	Protein: 74 mg% Glucose:110 mg%	Mild degenerative changes.	IVIG: 2 g/kg over 5 days with supportive treatment	Deteriorated over the course of treatment.
			Cells = 0 cells/cmm.	No Cord changes
				No nerve root enhancement		Day 2 into IVIg therapy, power in all 4 limbs had reduced to grade 1/5 and patient developed severe respiratory distress requiring intubation and mechanical ventilation.
						His respiratory involvement due to Covid-19 also continued to worsen and the patient expired after
						7 days of hospital admission.
3	Normal	Axonal sensorimotor polyneuropathy affecting all 4 limbs	Protein: 84 mg% glucose: 94 mg%	Mild degenerative changes.	IVIG: 2 g/kg over 5 days	Good improvement (Able to walk independently at discharge)
			Cells = 5 cells/cmm; all lymphocytes	No Cord changes
				No contrast enhancement
4	Bilateral lower and midzone infiltrates	Pure motor demyelinating polyneuropathy involving all 4 limb and bifacial demyelinating neuropathy.	Protein: 52 mg%;	Mild degenerative changes.	IVIG: 2 g/kg over 5 days	Good improvement (Able to walk independently at discharge)
			Glucose: 54 mg%
			Cells: <5 cells/cmm; all lymphocytes	No Cord changes